Head-To-Head Contrast: Atyr PHARMA (ATYR) vs. The Competition
Atyr PHARMA (NASDAQ:ATYR – Get Free Report) is one of 292 publicly-traded companies in the “Biological products, except diagnostic” industry, but how does it weigh in compared to its rivals? We will compare Atyr PHARMA to similar businesses based on the strength of its institutional ownership, analyst recommendations, dividends, earnings, valuation, risk and profitability. Insider […]
More Stories
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. Announces Monthly Dividend of $0.04 (NYSE:DCF)
BNY Mellon Alcentra Global Credit Income 2024 Target Term Fund, Inc. (NYSE:DCF – Get Free Report) declared a monthly dividend...
First Trust Alternative Absolute Return Strategy ETF (FAAR) to Issue Quarterly Dividend of $0.20 on September 30th
First Trust Alternative Absolute Return Strategy ETF (NASDAQ:FAAR – Get Free Report) declared a quarterly dividend on Wednesday, September 25th,...
First Trust Capital Strength ETF (FTCS) To Go Ex-Dividend on September 26th
First Trust Capital Strength ETF (NASDAQ:FTCS – Get Free Report) announced a quarterly dividend on Wednesday, September 25th, NASDAQ reports....
AGM Group Holdings Inc. (NASDAQ:AGMH) Short Interest Update
AGM Group Holdings Inc. (NASDAQ:AGMH – Get Free Report) was the recipient of a large growth in short interest in...
Raffles Medical Group Ltd (OTCMKTS:RAFLF) Sees Significant Decrease in Short Interest
Raffles Medical Group Ltd (OTCMKTS:RAFLF – Get Free Report) was the recipient of a significant decrease in short interest in...
Short Interest in Legrand SA (OTCMKTS:LGRDY) Decreases By 90.6%
Legrand SA (OTCMKTS:LGRDY – Get Free Report) was the target of a large decline in short interest in September. As...